Taiwan · Delayed Price · Currency is TWD InnoPharmax Statistics
Total Valuation
InnoPharmax has a market cap or net worth of TWD 1.57 billion. The enterprise value is 1.42 billion.
| Market Cap | 1.57B |
| Enterprise Value | 1.42B |
Important Dates
The next estimated earnings date is Monday, August 10, 2026.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InnoPharmax has 107.58 million shares outstanding. The number of shares has increased by 10.78% in one year.
| Current Share Class | 107.58M |
| Shares Outstanding | 107.58M |
| Shares Change (YoY) | +10.78% |
| Shares Change (QoQ) | +7.62% |
| Owned by Insiders (%) | 2.08% |
| Owned by Institutions (%) | 4.43% |
| Float | 81.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.69 |
| PB Ratio | 3.73 |
| P/TBV Ratio | 3.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.71 |
| EV / Sales | 20.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.57 |
Financial Position
The company has a current ratio of 3.52, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.52 |
| Quick Ratio | 3.16 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.08 |
| Interest Coverage | -448.46 |
Financial Efficiency
Return on equity (ROE) is -36.08% and return on invested capital (ROIC) is -20.48%.
| Return on Equity (ROE) | -36.08% |
| Return on Assets (ROA) | -19.48% |
| Return on Invested Capital (ROIC) | -20.48% |
| Return on Capital Employed (ROCE) | -40.98% |
| Weighted Average Cost of Capital (WACC) | 4.51% |
| Revenue Per Employee | 2.09M |
| Profits Per Employee | -5.59M |
| Employee Count | 33 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 3.43 |
Taxes
In the past 12 months, InnoPharmax has paid 3.51 million in taxes.
| Income Tax | 3.51M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.27% in the last 52 weeks. The beta is 0.05, so InnoPharmax's price volatility has been lower than the market average.
| Beta (5Y) | 0.05 |
| 52-Week Price Change | -2.27% |
| 50-Day Moving Average | 15.11 |
| 200-Day Moving Average | 17.58 |
| Relative Strength Index (RSI) | 51.04 |
| Average Volume (20 Days) | 260,361 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoPharmax had revenue of TWD 68.99 million and -184.40 million in losses. Loss per share was -1.71.
| Revenue | 68.99M |
| Gross Profit | 9.83M |
| Operating Income | -171.76M |
| Pretax Income | -180.89M |
| Net Income | -184.40M |
| EBITDA | -165.44M |
| EBIT | -171.76M |
| Loss Per Share | -1.71 |
Balance Sheet
The company has 154.86 million in cash and 10.82 million in debt, with a net cash position of 144.04 million or 1.34 per share.
| Cash & Cash Equivalents | 154.86M |
| Total Debt | 10.82M |
| Net Cash | 144.04M |
| Net Cash Per Share | 1.34 |
| Equity (Book Value) | 419.18M |
| Book Value Per Share | 3.88 |
| Working Capital | 125.70M |
Cash Flow
In the last 12 months, operating cash flow was -134.19 million and capital expenditures -276,000, giving a free cash flow of -134.47 million.
| Operating Cash Flow | -134.19M |
| Capital Expenditures | -276,000 |
| Depreciation & Amortization | 6.33M |
| Net Borrowing | -4.57M |
| Free Cash Flow | -134.47M |
| FCF Per Share | -1.25 |
Margins
Gross margin is 14.25%, with operating and profit margins of -248.98% and -267.29%.
| Gross Margin | 14.25% |
| Operating Margin | -248.98% |
| Pretax Margin | -262.21% |
| Profit Margin | -267.29% |
| EBITDA Margin | -239.81% |
| EBIT Margin | -248.98% |
| FCF Margin | n/a |
Dividends & Yields
InnoPharmax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.78% |
| Shareholder Yield | -10.78% |
| Earnings Yield | -11.78% |
| FCF Yield | -8.59% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |